What question did this study set out to answer?

Assess clinical preferences and decision-making factors for co-amoxiclav and cefuroxime among clinicians in India.

Expert Perspectives on the Usage of Co-amoxiclav and Cefuroxime in Clinical Practice: A Cross-Sectional Survey from Indian Settings

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional survey assesses clinician preferences for co-amoxiclav and cefuroxime in Indian settings, highlighting key decision factors.

Assess clinical preferences and decision-making factors for co-amoxiclav and cefuroxime among clinicians in India.
Cross-sectional survey conducted among clinicians across India
Utilized a 22-item structured questionnaire
Analyzed data using descriptive statistics.
49% of clinicians recommended co-amoxiclav for streptococcal pharyngitis.
60% preferred co-amoxiclav for adult CAP in patients without comorbidities.
76% favored co-amoxiclav for mild to moderate cellulitis in diabetic patients.

Manjula et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Cross-sectional survey assesses clinician preferences for co-amoxiclav and cefuroxime in Indian settings, highlighting key decision factors.